ExonHit Signs an Exclusive Agreement with Genmab for Novel Splice Variant Targets in Breast Cancer

Published June 14, 2010

ExonHit Signs an Exclusive Agreement with Genmab for Novel Splice Variant Targets in Breast Cancer
PARIS—-Regulatory News: ExonHit applied its genome-wide SpliceArray™ technology to develop a unique database in breast cancer Genmab retains exclusive rights on 10 novel splice events to fuel its antibody discovery activity ExonHit can further exploit the database to develop new drug candidates internally or through partnerships